High-Sensitivity Troponin T and Soluble Form of AXL as Long-Term Prognostic Biomarkers after Heart Transplantation
Table 1
Demographic and clinical characteristics and biomarkers in 96 HTx patients subdivided according to occurrence or absence of cardiovascular events.
Variables
All
No events
Events
No events versus events
Recipient age at HTx (years)
47 ± 16
49 ± 15
44 ± 16
0.19
Donor age (years)
40 ± 15
39 ± 13
42 ± 15
0.4
Total ischemic time (min)
183 ± 54
186 ± 52
168 ± 61
0.1
Score rejection (%)
12 ± 14
13 ± 17
12 ± 13
0.9
Cytomegalovirus infection (%)
35 (35%)
29 (39%)
6 (30%)
0.6
Plasma creatinine, umol/L
125 ± 106
104 ± 44
159 ± 120
0.002
Cardiovascular risk factors
Pre-HTx hyperlipemia (%)
28 (29%)
18 (26%)
10 (55%)
0.02
Post-HTx hypertension (%)
53 (55%)
39 (55%)
14 (78%)
0.7
Post-HTx diabetes (%)
27 (28%)
22 (31%)
6 (33%)
0.1
CAV
51 (53%)
30 (40%)
21 (100%)
Hs-cTnT (ng/L)
25 ± 27
20 ± 18
56 ± 45
0.04
sAXL (ng/L)
72 ± 35
26 ± 26
98 ± 51
0.01
HTx: heart transplantation; CAV: cardiac allograft vasculopathy; hs-cTnT: cardiac troponin T measured with methods of high sensitivity; sAXL: soluble form of the AXL receptor.
